Etokimab

Phase 2Monoclonal antibody

AAnaptysBio, Inc.

Etokimab is one of 100 small molecule programs targeting Allergy. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

AllergyActive, not recruiting

Chronic Rhinosinusitis With Nasal PolypsActive, not recruiting

Atopic DermatitisActive, not recruiting

AsthmaActive, not recruiting

AllergyPhase 2

Active, not recruiting

Chronic Rhinosinusitis With Nasal PolypsPhase 2

Active, not recruiting

Atopic DermatitisPhase 2

Active, not recruiting

AsthmaPhase 2

Active, not recruiting

Competition

Competitive Landscape

1050 competitors in Asthma

#DrugCompanyPhaseTrials

Singulair

AstraZeneca

Preclinical

17 2

Cinqair

Teva

Preclinical

13 3

Dupixent

AAzienda U.S.L. 1 di Massa e Carrara

Preclinical

30 4

Etokimab

AAnaptysBio, Inc.

Phase 2

1 5

Asmanex

Novartis

Preclinical

5 6

Arcoxia

Symbicort

6 8

Aciphex

Akero Therapeutics

Preclinical

2 9

Atrovent

Boehringer Ingelheim

Preclinical

2 10

Decadron

QQuince Therapeutics S.p.A.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Allergy1 trial

Study to Investigate Etokimab (ANB020) Activity in Adult Participants With Peanut Allergy

Completed·AAnaptysBio, Inc.·Phase 2·NCT02920021·20 enrolled

Asthma1 trial

Proof of Concept Study to Investigate Etokimab (ANB020) Activity in Adult Participants With Severe Eosinophilic Asthma

Completed·AAnaptysBio, Inc.·Phase 2·NCT03469934·25 enrolled

Atopic Dermatitis1 trial

Efficacy, Safety, and Pharmacokinetic Profile of Etokimab (ANB020) in Adult Participants With Moderate-to-Severe Atopic Dermatitis

Completed·AAnaptysBio, Inc.·Phase 2·NCT03533751·302 enrolled

Chronic Rhinosinusitis With Nasal Polyps1 trial

Etokimab in Adults With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)

Completed·AAnaptysBio, Inc.·Phase 2·NCT03614923·105 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Etokimab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Etokimab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Etokimab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — AnaptysBio, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 2[1]
Company: AAnaptysBio, Inc.

Etokimab

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Allergy1 trial

Asthma1 trial

Atopic Dermatitis1 trial

Chronic Rhinosinusitis With Nasal Polyps1 trial

References

Drug Info

Quick Facts

Related News